Jason Butler
Stock Analyst at Citizens
(4.68)
# 169
Out of 5,182 analysts
142
Total ratings
51.7%
Success rate
47.9%
Average return
Main Sectors:
Stocks Rated by Jason Butler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVTX Avalo Therapeutics | Initiates: Market Outperform | $52 | $14.43 | +260.36% | 1 | Apr 6, 2026 | |
| CYTK Cytokinetics | Maintains: Market Outperform | $88 → $96 | $66.71 | +43.91% | 18 | Feb 25, 2026 | |
| IRWD Ironwood Pharmaceuticals | Upgrades: Market Outperform | $8 | $4.43 | +80.59% | 2 | Jan 5, 2026 | |
| NSRX Nasus Pharma | Initiates: Market Outperform | $19 | $2.24 | +748.21% | 1 | Dec 18, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Market Outperform | $114 → $131 | $120.16 | +9.02% | 5 | Dec 16, 2025 | |
| PRTA Prothena Corporation | Maintains: Market Outperform | $11 → $19 | $10.90 | +74.31% | 12 | Dec 1, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Market Outperform | $91 → $92 | $69.29 | +32.78% | 14 | Nov 4, 2025 | |
| AQST Aquestive Therapeutics | Maintains: Market Outperform | $9 → $12 | $4.32 | +177.78% | 8 | Oct 9, 2025 | |
| RAPP Rapport Therapeutics | Reiterates: Market Outperform | $28 | $39.71 | -29.49% | 2 | Jul 8, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Market Outperform | $37 | $22.17 | +66.89% | 15 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $39 | $18.34 | +112.65% | 5 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $6 | $3.98 | +50.75% | 11 | Jun 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $115 → $100 | $22.47 | +345.04% | 1 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $42 → $38 | $14.80 | +156.76% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $17 → $18 | $10.67 | +68.70% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $2.04 | +96.08% | 7 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $696 → $701 | $849.04 | -17.44% | 8 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $8 → $9 | $3.46 | +160.12% | 8 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $7.39 | +157.10% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $6.73 | - | 1 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $42,000 | $6.46 | +650,054.80% | 1 | Dec 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $111 → $116 | $14.01 | +727.98% | 4 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $9 | $4.72 | +90.68% | 1 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.91 | - | 1 | Dec 2, 2020 |
Avalo Therapeutics
Apr 6, 2026
Initiates: Market Outperform
Price Target: $52
Current: $14.43
Upside: +260.36%
Cytokinetics
Feb 25, 2026
Maintains: Market Outperform
Price Target: $88 → $96
Current: $66.71
Upside: +43.91%
Ironwood Pharmaceuticals
Jan 5, 2026
Upgrades: Market Outperform
Price Target: $8
Current: $4.43
Upside: +80.59%
Nasus Pharma
Dec 18, 2025
Initiates: Market Outperform
Price Target: $19
Current: $2.24
Upside: +748.21%
ABIVAX Société Anonyme
Dec 16, 2025
Maintains: Market Outperform
Price Target: $114 → $131
Current: $120.16
Upside: +9.02%
Prothena Corporation
Dec 1, 2025
Maintains: Market Outperform
Price Target: $11 → $19
Current: $10.90
Upside: +74.31%
Halozyme Therapeutics
Nov 4, 2025
Maintains: Market Outperform
Price Target: $91 → $92
Current: $69.29
Upside: +32.78%
Aquestive Therapeutics
Oct 9, 2025
Maintains: Market Outperform
Price Target: $9 → $12
Current: $4.32
Upside: +177.78%
Rapport Therapeutics
Jul 8, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $39.71
Upside: -29.49%
ACADIA Pharmaceuticals
Jun 26, 2025
Reiterates: Market Outperform
Price Target: $37
Current: $22.17
Upside: +66.89%
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $39
Current: $18.34
Upside: +112.65%
Jun 12, 2025
Reiterates: Market Outperform
Price Target: $6
Current: $3.98
Upside: +50.75%
May 9, 2025
Maintains: Market Outperform
Price Target: $115 → $100
Current: $22.47
Upside: +345.04%
May 7, 2025
Maintains: Market Outperform
Price Target: $42 → $38
Current: $14.80
Upside: +156.76%
Mar 12, 2025
Maintains: Market Outperform
Price Target: $17 → $18
Current: $10.67
Upside: +68.70%
Mar 5, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $2.04
Upside: +96.08%
Feb 28, 2025
Maintains: Outperform
Price Target: $696 → $701
Current: $849.04
Upside: -17.44%
Feb 13, 2025
Maintains: Market Outperform
Price Target: $8 → $9
Current: $3.46
Upside: +160.12%
Apr 9, 2024
Reiterates: Market Outperform
Price Target: $19
Current: $7.39
Upside: +157.10%
Oct 17, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $6.73
Upside: -
Dec 15, 2021
Initiates: Market Outperform
Price Target: $42,000
Current: $6.46
Upside: +650,054.80%
Nov 23, 2021
Maintains: Market Outperform
Price Target: $111 → $116
Current: $14.01
Upside: +727.98%
Nov 8, 2021
Maintains: Market Outperform
Price Target: $7 → $9
Current: $4.72
Upside: +90.68%
Dec 2, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $2.91
Upside: -